Mobocertinib Approved in China for Patients with EGFR Exon20 Insertion+ NSCLC
The National Medical Products Administration (NMPA) of China has approved the oral tyrosine kinase inhibitor (TKI) mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Mobocertinib was reviewed as part of the NMPA’s Breakthrough Therapy program and is now the first and only treatment available for this patient population in China.
The approval is based on the results from the platinum-pretreated population in the Phase 1/2 trial of mobocertinib,1 which included 114 patients with EGFR Exon20 insertion+ NSCLC who received prior platinum-based therapy and were treated at the 160 mg dose. Results demonstrated a confirmed overall response rate of 28% as well as a median duration of response of 15.8 months, a median overall survival of 20.2 months and a median progression-free survival of 7.3 months. The most common treatment-related adverse reactions were diarrhea (92%), rash (46%), paronychia (38%), and decreased appetite (37%).
Deadline Approaching for IASLC 2023 Lectureship and Distinguished Service Award Nominations
The IASLC Nominating Committee invites all IASLC Members to submit nominations for the 2023 Lectureship Awards and the 2023 Distinguished Service Awards. The deadline to nominate colleagues is Wednesday, February 1. Self-nominations are also allowed. The deadline to self-nominate and/or to accept a nomination is Wednesday, February, 15.
The IASLC Lectureship Awards recognize IASLC member leaders in the field who are making outstanding contributions within the lung cancer community through exemplary work in their careers. The IASLC Lectureship Awards are selected from qualifying representatives of the IASLC membership who represent specialty, geographic, and gender diversity.
Each IASLC Member may nominate up to five qualified individuals, including themselves, for this honor. Lectureship Awardees will be presented at the annual World Conference on Lung Cancer (WCLC). Awardees receive complimentary WCLC registration, travel expense reimbursement, and one year of complimentary IASLC membership. Find more information and submit nominations for the IASLC Lectureship Awards here.
The IASLC Distinguished Service Awards recognize luminaries in the field of lung and thoracic cancers—those who are further along in their careers and more high-level in their field of work—for their outstanding contributions to the field and to the IASLC. The IASLC Distinguished Service Award recipients are selected from qualifying representatives of the IASLC membership who represent specialty, geographic, and gender diversity.
Each IASLC Member may nominate up to five qualified individuals, including themselves, for this honor. Distinguished Service Awardees will also be presented at WCLC. Awardees receive complimentary WCLC registration, travel expense reimbursement, and one year of complimentary IASLC membership. Find more information and submit nominations for the IASLC Distinguished Service Awards here.
References
1. Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761
